nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralidoxime—ACHE—kidney cancer	0.593	0.63	CbGaD
Pralidoxime—BCHE—kidney cancer	0.349	0.37	CbGaD
Pralidoxime—BCHE—Neurotransmitter Clearance In The Synaptic Cleft—ACHE—kidney cancer	0.00143	0.0775	CbGpPWpGaD
Pralidoxime—Inflammation—Everolimus—kidney cancer	0.00142	0.0351	CcSEcCtD
Pralidoxime—ACHE—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—kidney cancer	0.0014	0.0756	CbGpPWpGaD
Pralidoxime—Inflammation—Erlotinib—kidney cancer	0.00137	0.0339	CcSEcCtD
Pralidoxime—Muscular weakness—Everolimus—kidney cancer	0.000881	0.0218	CcSEcCtD
Pralidoxime—Haemoglobin—Pazopanib—kidney cancer	0.00088	0.0218	CcSEcCtD
Pralidoxime—Haemorrhage—Pazopanib—kidney cancer	0.000876	0.0217	CcSEcCtD
Pralidoxime—BCHE—Synthesis, secretion, and deacylation of Ghrelin—ACHE—kidney cancer	0.000782	0.0424	CbGpPWpGaD
Pralidoxime—ACHE—Synthesis, secretion, and deacylation of Ghrelin—BCHE—kidney cancer	0.000764	0.0414	CbGpPWpGaD
Pralidoxime—Muscular weakness—Sunitinib—kidney cancer	0.000736	0.0182	CcSEcCtD
Pralidoxime—Vision blurred—Pazopanib—kidney cancer	0.000718	0.0178	CcSEcCtD
Pralidoxime—BCHE—Synthesis of PC—ACHE—kidney cancer	0.000716	0.0388	CbGpPWpGaD
Pralidoxime—ACHE—Synthesis of PC—BCHE—kidney cancer	0.000699	0.0379	CbGpPWpGaD
Pralidoxime—Haemoglobin—Vinblastine—kidney cancer	0.000698	0.0173	CcSEcCtD
Pralidoxime—Haemoglobin—Everolimus—kidney cancer	0.000695	0.0172	CcSEcCtD
Pralidoxime—Haemorrhage—Vinblastine—kidney cancer	0.000694	0.0172	CcSEcCtD
Pralidoxime—Haemorrhage—Everolimus—kidney cancer	0.000691	0.0171	CcSEcCtD
Pralidoxime—Haemoglobin—Erlotinib—kidney cancer	0.00067	0.0166	CcSEcCtD
Pralidoxime—Haemorrhage—Erlotinib—kidney cancer	0.000667	0.0165	CcSEcCtD
Pralidoxime—Inflammation—Capecitabine—kidney cancer	0.000654	0.0162	CcSEcCtD
Pralidoxime—Muscular weakness—Vincristine—kidney cancer	0.000623	0.0154	CcSEcCtD
Pralidoxime—Haemoglobin—Sorafenib—kidney cancer	0.000603	0.0149	CcSEcCtD
Pralidoxime—Haemorrhage—Sorafenib—kidney cancer	0.0006	0.0149	CcSEcCtD
Pralidoxime—Hyperventilation—Doxorubicin—kidney cancer	0.000594	0.0147	CcSEcCtD
Pralidoxime—Somnolence—Temsirolimus—kidney cancer	0.000587	0.0145	CcSEcCtD
Pralidoxime—Haemoglobin—Sunitinib—kidney cancer	0.00058	0.0144	CcSEcCtD
Pralidoxime—Haemorrhage—Sunitinib—kidney cancer	0.000577	0.0143	CcSEcCtD
Pralidoxime—Vision blurred—Everolimus—kidney cancer	0.000567	0.014	CcSEcCtD
Pralidoxime—Pain—Temsirolimus—kidney cancer	0.000565	0.014	CcSEcCtD
Pralidoxime—Agitation—Everolimus—kidney cancer	0.000553	0.0137	CcSEcCtD
Pralidoxime—Somnolence—Pazopanib—kidney cancer	0.000553	0.0137	CcSEcCtD
Pralidoxime—Pain—Pazopanib—kidney cancer	0.000532	0.0132	CcSEcCtD
Pralidoxime—Muscular weakness—Paclitaxel—kidney cancer	0.000495	0.0122	CcSEcCtD
Pralidoxime—Tachycardia—Everolimus—kidney cancer	0.000479	0.0119	CcSEcCtD
Pralidoxime—Haemoglobin—Gemcitabine—kidney cancer	0.000466	0.0115	CcSEcCtD
Pralidoxime—Haemorrhage—Gemcitabine—kidney cancer	0.000463	0.0115	CcSEcCtD
Pralidoxime—Diplopia—Capecitabine—kidney cancer	0.00046	0.0114	CcSEcCtD
Pralidoxime—Somnolence—Everolimus—kidney cancer	0.000437	0.0108	CcSEcCtD
Pralidoxime—Dizziness—Temsirolimus—kidney cancer	0.000437	0.0108	CcSEcCtD
Pralidoxime—BCHE—Irinotecan Pathway—APC—kidney cancer	0.000432	0.0234	CbGpPWpGaD
Pralidoxime—Pain—Vinblastine—kidney cancer	0.000422	0.0104	CcSEcCtD
Pralidoxime—Inflammation—Doxorubicin—kidney cancer	0.000421	0.0104	CcSEcCtD
Pralidoxime—Pain—Everolimus—kidney cancer	0.00042	0.0104	CcSEcCtD
Pralidoxime—Headache—Temsirolimus—kidney cancer	0.000414	0.0102	CcSEcCtD
Pralidoxime—Dizziness—Pazopanib—kidney cancer	0.000411	0.0102	CcSEcCtD
Pralidoxime—Muscular weakness—Capecitabine—kidney cancer	0.000406	0.01	CcSEcCtD
Pralidoxime—Pain—Erlotinib—kidney cancer	0.000405	0.01	CcSEcCtD
Pralidoxime—ACHE—ATF-2 transcription factor network—JUND—kidney cancer	0.000393	0.0213	CbGpPWpGaD
Pralidoxime—Nausea—Temsirolimus—kidney cancer	0.000392	0.00971	CcSEcCtD
Pralidoxime—Agitation—Vincristine—kidney cancer	0.000391	0.00967	CcSEcCtD
Pralidoxime—Haemoglobin—Paclitaxel—kidney cancer	0.00039	0.00965	CcSEcCtD
Pralidoxime—Headache—Pazopanib—kidney cancer	0.00039	0.00965	CcSEcCtD
Pralidoxime—Haemorrhage—Paclitaxel—kidney cancer	0.000388	0.0096	CcSEcCtD
Pralidoxime—Nausea—Pazopanib—kidney cancer	0.00037	0.00915	CcSEcCtD
Pralidoxime—Pain—Sorafenib—kidney cancer	0.000365	0.00902	CcSEcCtD
Pralidoxime—Pain—Sunitinib—kidney cancer	0.000351	0.00868	CcSEcCtD
Pralidoxime—ACHE—Melatonin metabolism and effects—CYP1A1—kidney cancer	0.000345	0.0187	CbGpPWpGaD
Pralidoxime—Pain—Dactinomycin—kidney cancer	0.000332	0.00822	CcSEcCtD
Pralidoxime—Dizziness—Vinblastine—kidney cancer	0.000326	0.00807	CcSEcCtD
Pralidoxime—Dizziness—Everolimus—kidney cancer	0.000325	0.00804	CcSEcCtD
Pralidoxime—Haemoglobin—Capecitabine—kidney cancer	0.00032	0.00792	CcSEcCtD
Pralidoxime—Haemorrhage—Capecitabine—kidney cancer	0.000318	0.00788	CcSEcCtD
Pralidoxime—Vision blurred—Paclitaxel—kidney cancer	0.000318	0.00788	CcSEcCtD
Pralidoxime—ACHE—Peptide hormone metabolism—MME—kidney cancer	0.000316	0.0171	CbGpPWpGaD
Pralidoxime—Dizziness—Erlotinib—kidney cancer	0.000313	0.00776	CcSEcCtD
Pralidoxime—Agitation—Paclitaxel—kidney cancer	0.00031	0.00768	CcSEcCtD
Pralidoxime—Headache—Vinblastine—kidney cancer	0.000309	0.00765	CcSEcCtD
Pralidoxime—Headache—Everolimus—kidney cancer	0.000308	0.00762	CcSEcCtD
Pralidoxime—Headache—Erlotinib—kidney cancer	0.000297	0.00735	CcSEcCtD
Pralidoxime—Pain—Vincristine—kidney cancer	0.000297	0.00734	CcSEcCtD
Pralidoxime—Diplopia—Doxorubicin—kidney cancer	0.000297	0.00734	CcSEcCtD
Pralidoxime—Nausea—Vinblastine—kidney cancer	0.000293	0.00725	CcSEcCtD
Pralidoxime—Somnolence—Gemcitabine—kidney cancer	0.000293	0.00724	CcSEcCtD
Pralidoxime—Nausea—Everolimus—kidney cancer	0.000292	0.00722	CcSEcCtD
Pralidoxime—ACHE—Monoamine Transport—TSC2—kidney cancer	0.000283	0.0153	CbGpPWpGaD
Pralidoxime—Dizziness—Sorafenib—kidney cancer	0.000282	0.00698	CcSEcCtD
Pralidoxime—BCHE—Peptide hormone metabolism—MME—kidney cancer	0.000282	0.0153	CbGpPWpGaD
Pralidoxime—Pain—Gemcitabine—kidney cancer	0.000282	0.00697	CcSEcCtD
Pralidoxime—Nausea—Erlotinib—kidney cancer	0.000282	0.00697	CcSEcCtD
Pralidoxime—Dizziness—Sunitinib—kidney cancer	0.000271	0.00672	CcSEcCtD
Pralidoxime—Tachycardia—Paclitaxel—kidney cancer	0.000269	0.00666	CcSEcCtD
Pralidoxime—ACHE—ATF-2 transcription factor network—JUNB—kidney cancer	0.000267	0.0145	CbGpPWpGaD
Pralidoxime—Headache—Sorafenib—kidney cancer	0.000267	0.00661	CcSEcCtD
Pralidoxime—Muscular weakness—Doxorubicin—kidney cancer	0.000262	0.00648	CcSEcCtD
Pralidoxime—Vision blurred—Capecitabine—kidney cancer	0.000261	0.00646	CcSEcCtD
Pralidoxime—Headache—Sunitinib—kidney cancer	0.000257	0.00636	CcSEcCtD
Pralidoxime—Nausea—Sorafenib—kidney cancer	0.000253	0.00627	CcSEcCtD
Pralidoxime—Somnolence—Paclitaxel—kidney cancer	0.000245	0.00606	CcSEcCtD
Pralidoxime—Nausea—Sunitinib—kidney cancer	0.000244	0.00603	CcSEcCtD
Pralidoxime—Pain—Paclitaxel—kidney cancer	0.000236	0.00583	CcSEcCtD
Pralidoxime—Nausea—Dactinomycin—kidney cancer	0.000231	0.00571	CcSEcCtD
Pralidoxime—ACHE—Peptide hormone metabolism—PAX6—kidney cancer	0.00023	0.0125	CbGpPWpGaD
Pralidoxime—Dizziness—Vincristine—kidney cancer	0.000229	0.00568	CcSEcCtD
Pralidoxime—ACHE—Peptide hormone metabolism—CTSD—kidney cancer	0.000229	0.0124	CbGpPWpGaD
Pralidoxime—Drowsiness—Doxorubicin—kidney cancer	0.000229	0.00566	CcSEcCtD
Pralidoxime—Tachycardia—Capecitabine—kidney cancer	0.000221	0.00546	CcSEcCtD
Pralidoxime—Headache—Vincristine—kidney cancer	0.000217	0.00538	CcSEcCtD
Pralidoxime—BCHE—Peptide hormone metabolism—ACHE—kidney cancer	0.000216	0.0117	CbGpPWpGaD
Pralidoxime—ACHE—Peptide hormone metabolism—BCHE—kidney cancer	0.000211	0.0114	CbGpPWpGaD
Pralidoxime—BCHE—Glycerophospholipid biosynthesis—ACHE—kidney cancer	0.00021	0.0114	CbGpPWpGaD
Pralidoxime—Haemoglobin—Doxorubicin—kidney cancer	0.000206	0.00511	CcSEcCtD
Pralidoxime—Headache—Gemcitabine—kidney cancer	0.000206	0.0051	CcSEcCtD
Pralidoxime—Nausea—Vincristine—kidney cancer	0.000206	0.0051	CcSEcCtD
Pralidoxime—BCHE—Peptide hormone metabolism—PAX6—kidney cancer	0.000205	0.0111	CbGpPWpGaD
Pralidoxime—Haemorrhage—Doxorubicin—kidney cancer	0.000205	0.00508	CcSEcCtD
Pralidoxime—ACHE—Glycerophospholipid biosynthesis—BCHE—kidney cancer	0.000205	0.0111	CbGpPWpGaD
Pralidoxime—BCHE—Peptide hormone metabolism—CTSD—kidney cancer	0.000204	0.0111	CbGpPWpGaD
Pralidoxime—Nausea—Gemcitabine—kidney cancer	0.000196	0.00484	CcSEcCtD
Pralidoxime—Pain—Capecitabine—kidney cancer	0.000193	0.00479	CcSEcCtD
Pralidoxime—Dizziness—Paclitaxel—kidney cancer	0.000182	0.00451	CcSEcCtD
Pralidoxime—Headache—Paclitaxel—kidney cancer	0.000173	0.00427	CcSEcCtD
Pralidoxime—Vision blurred—Doxorubicin—kidney cancer	0.000168	0.00417	CcSEcCtD
Pralidoxime—Agitation—Doxorubicin—kidney cancer	0.000164	0.00406	CcSEcCtD
Pralidoxime—Nausea—Paclitaxel—kidney cancer	0.000164	0.00405	CcSEcCtD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	0.000154	0.00832	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	0.000154	0.00832	CbGpPWpGaD
Pralidoxime—Dizziness—Capecitabine—kidney cancer	0.00015	0.0037	CcSEcCtD
Pralidoxime—BCHE—Phospholipid metabolism—ACHE—kidney cancer	0.000146	0.00794	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	0.000146	0.00788	CbGpPWpGaD
Pralidoxime—ACHE—Phospholipid metabolism—BCHE—kidney cancer	0.000143	0.00775	CbGpPWpGaD
Pralidoxime—Tachycardia—Doxorubicin—kidney cancer	0.000142	0.00352	CcSEcCtD
Pralidoxime—Headache—Capecitabine—kidney cancer	0.000142	0.00351	CcSEcCtD
Pralidoxime—Nausea—Capecitabine—kidney cancer	0.000134	0.00333	CcSEcCtD
Pralidoxime—Somnolence—Doxorubicin—kidney cancer	0.00013	0.00321	CcSEcCtD
Pralidoxime—ACHE—Neuronal System—KCNMA1—kidney cancer	0.000126	0.00685	CbGpPWpGaD
Pralidoxime—Pain—Doxorubicin—kidney cancer	0.000125	0.00309	CcSEcCtD
Pralidoxime—ACHE—Metabolism of proteins—EIF5B—kidney cancer	0.000121	0.00654	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	0.000116	0.0063	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.000114	0.00617	CbGpPWpGaD
Pralidoxime—BCHE—Neuronal System—KCNMA1—kidney cancer	0.000113	0.00611	CbGpPWpGaD
Pralidoxime—ACHE—Peptide hormone metabolism—POMC—kidney cancer	0.000109	0.0059	CbGpPWpGaD
Pralidoxime—BCHE—Transmission across Chemical Synapses—ACHE—kidney cancer	0.000109	0.0059	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—EIF5B—kidney cancer	0.000108	0.00583	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—CUL7—kidney cancer	0.000108	0.00583	CbGpPWpGaD
Pralidoxime—ACHE—Transmission across Chemical Synapses—BCHE—kidney cancer	0.000106	0.00576	CbGpPWpGaD
Pralidoxime—ACHE—ATF-2 transcription factor network—CCND1—kidney cancer	0.000105	0.0057	CbGpPWpGaD
Pralidoxime—ACHE—ATF-2 transcription factor network—JUN—kidney cancer	0.000105	0.00568	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	0.000104	0.00566	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	0.000104	0.00566	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—HSPA9—kidney cancer	0.000103	0.00556	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.000102	0.0055	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	9.77e-05	0.00529	CbGpPWpGaD
Pralidoxime—BCHE—Peptide hormone metabolism—POMC—kidney cancer	9.72e-05	0.00527	CbGpPWpGaD
Pralidoxime—Dizziness—Doxorubicin—kidney cancer	9.64e-05	0.00239	CcSEcCtD
Pralidoxime—BCHE—Metabolism of proteins—CUL7—kidney cancer	9.59e-05	0.0052	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—HSPA9—kidney cancer	9.15e-05	0.00496	CbGpPWpGaD
Pralidoxime—Headache—Doxorubicin—kidney cancer	9.13e-05	0.00226	CcSEcCtD
Pralidoxime—ACHE—ATF-2 transcription factor network—MAPK3—kidney cancer	8.67e-05	0.0047	CbGpPWpGaD
Pralidoxime—Nausea—Doxorubicin—kidney cancer	8.66e-05	0.00214	CcSEcCtD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	8.58e-05	0.00465	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	8.5e-05	0.00461	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—MUC4—kidney cancer	8.36e-05	0.00453	CbGpPWpGaD
Pralidoxime—BCHE—Neuronal System—ACHE—kidney cancer	8.34e-05	0.00452	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—ABCB1—kidney cancer	8.31e-05	0.0045	CbGpPWpGaD
Pralidoxime—ACHE—ATF-2 transcription factor network—MAPK1—kidney cancer	8.25e-05	0.00447	CbGpPWpGaD
Pralidoxime—ACHE—Neuronal System—BCHE—kidney cancer	8.15e-05	0.00441	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—ST3GAL2—kidney cancer	7.95e-05	0.00431	CbGpPWpGaD
Pralidoxime—ACHE—Peptide hormone metabolism—CTNNB1—kidney cancer	7.77e-05	0.00421	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—EEF2—kidney cancer	7.77e-05	0.00421	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—MUC4—kidney cancer	7.46e-05	0.00404	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—ACY1—kidney cancer	7.31e-05	0.00396	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—ST3GAL2—kidney cancer	7.1e-05	0.00384	CbGpPWpGaD
Pralidoxime—BCHE—Peptide hormone metabolism—CTNNB1—kidney cancer	6.94e-05	0.00376	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—EEF2—kidney cancer	6.94e-05	0.00376	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—ACY1—kidney cancer	6.52e-05	0.00353	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	6.24e-05	0.00338	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—PDHB—kidney cancer	6.22e-05	0.00337	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	5.99e-05	0.00324	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—MME—kidney cancer	5.96e-05	0.00323	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—CCBL1—kidney cancer	5.85e-05	0.00317	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	5.56e-05	0.00301	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—PDHB—kidney cancer	5.55e-05	0.00301	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—RPL14—kidney cancer	5.54e-05	0.003	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—HSPD1—kidney cancer	5.54e-05	0.003	CbGpPWpGaD
Pralidoxime—ACHE—Transmission across Chemical Synapses—BRAF—kidney cancer	5.43e-05	0.00294	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—MME—kidney cancer	5.32e-05	0.00288	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—CCBL1—kidney cancer	5.22e-05	0.00283	CbGpPWpGaD
Pralidoxime—ACHE—Phospholipid metabolism—PTEN—kidney cancer	5.14e-05	0.00279	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—GLIPR1—kidney cancer	5.07e-05	0.00275	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—PPAT—kidney cancer	5.07e-05	0.00275	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	5e-05	0.00271	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	4.95e-05	0.00268	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—RPL14—kidney cancer	4.94e-05	0.00268	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—HSPD1—kidney cancer	4.94e-05	0.00268	CbGpPWpGaD
Pralidoxime—BCHE—Transmission across Chemical Synapses—BRAF—kidney cancer	4.84e-05	0.00262	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	4.72e-05	0.00256	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—APRT—kidney cancer	4.71e-05	0.00255	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—FH—kidney cancer	4.71e-05	0.00255	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	4.7e-05	0.00255	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	4.65e-05	0.00252	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	4.61e-05	0.0025	CbGpPWpGaD
Pralidoxime—BCHE—Phospholipid metabolism—PTEN—kidney cancer	4.59e-05	0.00249	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	4.55e-05	0.00246	CbGpPWpGaD
Pralidoxime—ACHE—Transmission across Chemical Synapses—RAF1—kidney cancer	4.53e-05	0.00245	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—GLIPR1—kidney cancer	4.52e-05	0.00245	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—PPAT—kidney cancer	4.52e-05	0.00245	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—EIF4EBP1—kidney cancer	4.52e-05	0.00245	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	4.46e-05	0.00242	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—GPC3—kidney cancer	4.43e-05	0.0024	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	4.42e-05	0.00239	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—PAX6—kidney cancer	4.35e-05	0.00235	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—CTSD—kidney cancer	4.32e-05	0.00234	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—CA2—kidney cancer	4.31e-05	0.00233	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	4.31e-05	0.00233	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—FH—kidney cancer	4.2e-05	0.00228	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—APRT—kidney cancer	4.2e-05	0.00228	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—ALAD—kidney cancer	4.2e-05	0.00228	CbGpPWpGaD
Pralidoxime—ACHE—Neuronal System—BRAF—kidney cancer	4.16e-05	0.00225	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	4.11e-05	0.00223	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—ST3GAL2—kidney cancer	4.1e-05	0.00222	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	4.1e-05	0.00222	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—ACHE—kidney cancer	4.08e-05	0.00221	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	4.07e-05	0.0022	CbGpPWpGaD
Pralidoxime—BCHE—Transmission across Chemical Synapses—RAF1—kidney cancer	4.04e-05	0.00219	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—EIF4EBP1—kidney cancer	4.03e-05	0.00218	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—ALDH1A1—kidney cancer	4.01e-05	0.00217	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—BCHE—kidney cancer	3.98e-05	0.00216	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	3.97e-05	0.00215	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—GPC3—kidney cancer	3.95e-05	0.00214	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—PAX6—kidney cancer	3.88e-05	0.0021	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—CTSD—kidney cancer	3.86e-05	0.00209	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—CA2—kidney cancer	3.85e-05	0.00208	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—SLC5A3—kidney cancer	3.84e-05	0.00208	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—PGK1—kidney cancer	3.84e-05	0.00208	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—LDHB—kidney cancer	3.77e-05	0.00204	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—ALAD—kidney cancer	3.75e-05	0.00203	CbGpPWpGaD
Pralidoxime—BCHE—Neuronal System—BRAF—kidney cancer	3.71e-05	0.00201	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—ST3GAL2—kidney cancer	3.66e-05	0.00198	CbGpPWpGaD
Pralidoxime—ACHE—Phospholipid metabolism—PIK3CA—kidney cancer	3.63e-05	0.00197	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	3.58e-05	0.00194	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—ALDH1A1—kidney cancer	3.57e-05	0.00194	CbGpPWpGaD
Pralidoxime—ACHE—Neuronal System—RAF1—kidney cancer	3.47e-05	0.00188	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—PGK1—kidney cancer	3.43e-05	0.00186	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—SLC5A3—kidney cancer	3.43e-05	0.00186	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	3.39e-05	0.00184	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—LDHB—kidney cancer	3.36e-05	0.00182	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	3.3e-05	0.00179	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—CA9—kidney cancer	3.27e-05	0.00177	CbGpPWpGaD
Pralidoxime—BCHE—Phospholipid metabolism—PIK3CA—kidney cancer	3.24e-05	0.00175	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	3.22e-05	0.00175	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	3.19e-05	0.00173	CbGpPWpGaD
Pralidoxime—ACHE—Transmission across Chemical Synapses—MAPK1—kidney cancer	3.11e-05	0.00168	CbGpPWpGaD
Pralidoxime—BCHE—Neuronal System—RAF1—kidney cancer	3.1e-05	0.00168	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—IGF2—kidney cancer	3.08e-05	0.00167	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	3.04e-05	0.00165	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—CA9—kidney cancer	2.91e-05	0.00158	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.85e-05	0.00154	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	2.8e-05	0.00152	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—CRABP1—kidney cancer	2.78e-05	0.0015	CbGpPWpGaD
Pralidoxime—BCHE—Transmission across Chemical Synapses—MAPK1—kidney cancer	2.77e-05	0.0015	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—IGF2—kidney cancer	2.75e-05	0.00149	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	2.71e-05	0.00147	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—ITPR2—kidney cancer	2.58e-05	0.0014	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—CRABP1—kidney cancer	2.48e-05	0.00134	CbGpPWpGaD
Pralidoxime—ACHE—Neuronal System—MAPK1—kidney cancer	2.38e-05	0.00129	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.38e-05	0.00129	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—GSTT1—kidney cancer	2.35e-05	0.00128	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—ITPR2—kidney cancer	2.3e-05	0.00125	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—SCARB1—kidney cancer	2.23e-05	0.00121	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—PTGS1—kidney cancer	2.21e-05	0.0012	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—PSMD7—kidney cancer	2.16e-05	0.00117	CbGpPWpGaD
Pralidoxime—BCHE—Neuronal System—MAPK1—kidney cancer	2.12e-05	0.00115	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.12e-05	0.00115	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—GSTT1—kidney cancer	2.1e-05	0.00114	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—ACHE—kidney cancer	2.1e-05	0.00114	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—POMC—kidney cancer	2.06e-05	0.00111	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—BCHE—kidney cancer	2.05e-05	0.00111	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—SLC5A5—kidney cancer	2.03e-05	0.0011	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—SCARB1—kidney cancer	1.99e-05	0.00108	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—PTGS1—kidney cancer	1.97e-05	0.00107	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—SLC2A1—kidney cancer	1.96e-05	0.00106	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—PSMD7—kidney cancer	1.93e-05	0.00105	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.9e-05	0.00103	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—POMC—kidney cancer	1.83e-05	0.000994	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—SLC5A5—kidney cancer	1.81e-05	0.000979	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—SLC2A1—kidney cancer	1.75e-05	0.000946	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.69e-05	0.000918	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.66e-05	0.000897	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—GSTP1—kidney cancer	1.63e-05	0.000884	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—ABCB1—kidney cancer	1.54e-05	0.000837	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—GSTM1—kidney cancer	1.5e-05	0.000813	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.48e-05	0.0008	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—CTNNB1—kidney cancer	1.47e-05	0.000795	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—GSTP1—kidney cancer	1.46e-05	0.000789	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—CYP1A1—kidney cancer	1.42e-05	0.00077	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—ABCB1—kidney cancer	1.38e-05	0.000747	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—GSTM1—kidney cancer	1.34e-05	0.000725	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—CTNNB1—kidney cancer	1.31e-05	0.000709	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—CYP1A1—kidney cancer	1.27e-05	0.000687	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.17e-05	0.000633	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—POMC—kidney cancer	1.06e-05	0.000574	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.04e-05	0.000565	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—POMC—kidney cancer	9.46e-06	0.000512	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—PTGS2—kidney cancer	8.46e-06	0.000458	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—PTGS2—kidney cancer	7.54e-06	0.000409	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—PTEN—kidney cancer	7.37e-06	0.000399	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—PTEN—kidney cancer	6.58e-06	0.000356	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—PIK3CA—kidney cancer	5.2e-06	0.000282	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—PIK3CA—kidney cancer	4.64e-06	0.000251	CbGpPWpGaD
